Biogen Inc. (FRA:IDP)
Germany · Delayed Price · Currency is EUR | Market Cap | 33.08B +77.3% |
| Revenue (ttm) | 8.78B +0.3% |
| Net Income | 730.53M -45.5% |
| EPS | 5.03 -46.1% |
| Shares Out | n/a |
| PE Ratio | 43.68 |
| Forward PE | 18.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26 |
| Open | 229.10 |
| Previous Close | 224.00 |
| Day's Range | 219.80 - 229.10 |
| 52-Week Range | 126.35 - 229.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial numbers in USD Financial StatementsNews
Biogen price target raised to $244 from $219 at BofA
BofA raised the firm’s price target on Biogen (BIIB) to $244 from $219 and keeps a Neutral rating on the shares. Q3 is “likely to be relatively quiet” and the…
Biogen price target raised to $250 from $225 at TD Cowen
TD Cowen raised the firm’s price target on Biogen (BIIB) to $250 from $225 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3…
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, in...
Biogen price target raised to $220 from $208 at BMO Capital
BMO Capital raised the firm’s price target on Biogen (BIIB) to $220 from $208 and keeps a Market Perform rating on the shares. Sentiment for Biogen is at a multi-year-high,…
Biogen upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Biogen (BIIB) to Overweight from Neutral with a price target of $300, up from $210. The firm see an “increasingly compelling catalyst path” and an improved long-term growth…
Biogen price target raised to $270 from $240 at UBS
UBS raised the firm’s price target on Biogen (BIIB) to $270 from $240 and keeps a Buy rating on the shares. The firm previewed Q3 earnings for the U.S. pharma…
Biogen price target lowered to $256 from $260 at RBC Capital
RBC Capital lowered the firm’s price target on Biogen (BIIB) to $256 from $260 and keeps an Outperform rating on the shares as part of a broader research note adjusting…
AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
AI startup BioinvestGPT predicted the failure of Novartis AG’s ($NVS) experimental muscular dystrophy drug months before a disappointing Phase 3 result sent the drugmaker’s shares down 11% and erased ...
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
ProMIS Neurosciences appoints Ivana Rubino as chief commercial officer
ProMIS Neurosciences (PMN) announced the appointment of Ivana Rubino as chief commercial officer, effective October 5. During her time at Biogen (BIIB) and F. Hoffmann-La Roche, Rubino led and helped…
Biogen's experimental lupus drug shows benefit against skin symptoms
Biogen said on Friday its experimental drug showed durable improvement in skin symptoms among patients with a type of autoimmune disease in a mid-stage study.
Biogen says litifilimab demonstrates rapid, durable efficacy in Phase 2 data
Biogen (BIIB) announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study of litifilimab in people living with cutaneous lupus erythematosus. The updated results, presented...
Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in ...
Biogen publishes results from adolescent subgroup of VALIANT study
Biogen (BIIB) announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating Empaveli in the Clinical Journal of the American Society of…
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study...
Eisai, Biogen announce Leqembi Pen has been approved in Japan
Eisai (ESAIY) and Biogen (BIIB) announced that Leqembi Pen, the subcutaneous formulation of the anti-amyloid beta protofibril antibody Leqembi has been approved in Japan as a new route of administrati...
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease
The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease The First and Only Anti-Amyloid Treatment in Japan that Enable At-H...
Biogen Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has transformed its strategy, expanding beyond neuroscience into immunology, nephrology, and other specialties through targeted acquisitions and pipeline diversification. Key assets like LEQEMBI, litifilimab, and felzartamab are expected to drive growth, with multiple late-stage trials and commercial launches anticipated over the next several years.
Biogen price target raised to $175 from $165 at HSBC
HSBC raised the firm’s price target on Biogen (BIIB) to $175 from $165 and keeps a Reduce rating on the shares. The firm adjusted targets in the healthcare group to…
Biogen Transcript: Wells Fargo 21st Annual Healthcare Conference
Management highlighted strategic diversification beyond neurology, disciplined capital allocation, and operational efficiency. Key growth drivers include a robust late-stage pipeline, expansion into nephrology and immunology, and commercial execution of new assets like felzartamab and SYFOVRE.
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
“Stoke Therapeutics (STOK) and Biogen Inc. (BIIB) announced presentations of data at the 16th European Epilepsy Congress taking place September 5-9 in Athens, Greece. These data support the potential ...
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
Biogen price target raised to $245 from $225 at Piper Sandler
Piper Sandler raised the firm’s price target on Biogen (BIIB) to $245 from $225 and keeps an Overweight rating on the shares. The firm cites post-Q2 model updates for the…
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
Eisai (ESAIY) and Biogen (BIIB) announced that the National Medical Products Administration of China has approved the subcutaneous formulation, the anti-amyloid beta protofibril antibody Leqembi, as a...
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease The First and Only Anti-Amyloid Therapy in China t...